Log In
Print this Print this

Blincyto, blinatumomab (AMG 103) (formerly MT103)

Also known as: formerly MEDI-538

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionBispecific T cell engager (BiTE) against CD19
Molecular Target CD19
Mechanism of ActionImmunotherapy; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today